Related Experiment Video
Updated: Jun 28, 2026
The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
Published on: May 17, 2024
TRC4149 a novel advanced glycation end product breaker improves hemodynamic status in diabetic spontaneously
P Pathak1, R Gupta, A Chaudhari
1Torrent Research Centre, P.O. Bhat, Dist.Gandhinagar -382428, Gujarat, India.
Objective:
Advanced Glycation Endproducts (AGEs), implicated as one of the major causes of diabetic complications, either directly or via receptor mediated actions, trigger downstream events in the conduit vessels, microvascular bed as well as myocardium leading to microvascular and cardiac dysfunction. The aim of this study was to characterise the activity profile of TRC4149, a novel AGE breaker compound, to determine its ability to reduce the burden of AGEs in vitro and in vivo and to evaluate whether the reduced AGE burden could translate into improvement in hemodynamic function in a model of Streptozotocin induced diabetic Spontaneously Hypertensive Rats (SHR).
Method:
AGEs were prepared in vitro by incubating BSA and lysozyme with glucose or ribose while AGE-LDL was generated by copper catalyzed LDL oxidation. TRC4149 was evaluated using in vitro assays to determine its capacity to reduce the burden of AGEs and to test its antioxidant activity. To study the effect of TRC4149 on hemodynamic function, diabetic SHR implanted with telemetry transmitter were treated with TRC4149 (20 mg/kg i.p., b.i.d.) or vehicle for 14 weeks. Losartan was administered once per week and blood pressure was monitored telemetrically throughout the treatment period. Cardiac indices of systolic and diastolic function were assessed terminally using MacLab system. AGE load in aorta was determined immunohistochemically and VCAM expression was quantitated by real time PCR analysis.
Results:
TRC4149 was able to break preformed AGEs as well as reduce further AGE accumulation in vitro in a dose dependent manner. It also demonstrated a potent free radical scavenging activity. In diabetic SHR, treatment with TRC4149 retarded the decline in response to losartan over the study period, and also improved cardiac function as evidenced by an improved dP/dtmax/min, left ventricular systolic pressure and decreased left ventricular diastolic pressure as compared to untreated group. AGE load as well as VCAM expression in aorta was also reduced upon treatment.
Conclusions:
TRC4149, a novel AGE-breaker compound, by virtue of reducing AGE load preserved endothelial and cardiac function in diabetic SHR, a model that recapitulates the microvascular and cardiac dysfunction associated with hypertension along with long-term diabetes.
Insights
This study shows TRC4149, an advanced glycation endproduct (AGE) breaker, reduces AGE burden and improves cardiac function in diabetic rats. This novel compound preserves endothelial and cardiac health in a model of diabetes and hypertension.
Area of Science:
- Biochemistry
- Cardiovascular Research
- Pharmacology
Background:
- Advanced Glycation Endproducts (AGEs) contribute significantly to diabetic complications, causing dysfunction in blood vessels and the heart.
- Receptor-mediated actions of AGEs trigger detrimental downstream events, leading to microvascular and cardiac issues.
Purpose of the Study:
- To characterize the activity of TRC4149, a novel AGE breaker compound.
- To determine TRC4149's efficacy in reducing AGE burden both in vitro and in vivo.
- To evaluate if reduced AGE burden improves hemodynamic function in a rat model of diabetes and hypertension.
Main Methods:
- In vitro assays assessed TRC4149's ability to break preformed AGEs and inhibit AGE accumulation, alongside its antioxidant capacity.
- Diabetic Spontaneously Hypertensive Rats (SHR) were treated with TRC4149 for 14 weeks, with blood pressure and cardiac function monitored.
- Immunohistochemistry and real-time PCR were used to quantify AGE load and VCAM expression in the aorta.
Main Results:
- TRC4149 dose-dependently broke preformed AGEs and reduced further accumulation in vitro, also exhibiting potent free radical scavenging activity.
- In diabetic SHR, TRC4149 treatment improved cardiac function, evidenced by enhanced dP/dtmax/min and improved systolic/diastolic pressures.
- Aortic AGE load and VCAM expression were significantly reduced following TRC4149 treatment.
Conclusions:
- TRC4149 effectively reduces the AGE burden, preserving both endothelial and cardiac function.
- The compound demonstrates therapeutic potential in managing microvascular and cardiac dysfunction associated with long-term diabetes and hypertension.
Related Concept Videos
01:28Diabetic Nephropathy
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:27Diabetic Retinopathy